Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Masayuki Furukawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1278-0775; OpenAlex author ID A5103870713. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
129
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 20

  1. Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. Last author DOI 10.1200/po-25-01104↗
  2. Adjuvant S-1 Plus Metformin after Pancreatic Cancer Resection: A Multicenter Randomized Phase II Trial Co-author DOI 10.21203/rs.3.rs-9445035/v1↗
  3. Hypercoagulability Predicts Survival and Reflects NET-Associated Thromboinflammation in Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers18132120↗
  4. Pancreatic cancer secondary to biliary tract cancer associated with pancreaticobiliary maljunction: intraductal dissemination through the common channel. Co-author DOI 10.1007/s12328-025-02108-z↗
  5. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  6. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  7. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  8. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  9. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  10. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  11. Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of a… Last author DOI 10.1111/ajco.13669↗
  12. Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic… Co-author DOI 10.3390/jcm11175084↗
  13. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  14. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  15. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  16. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  17. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer. Co-author DOI 10.3892/ijo.2017.3992↗
  18. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  19. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  20. Giardiasis in the pancreas accompanied by pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3181f6a1b9↗

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lingaku Lee · 5 shared papers, 2011–2026 · strength 1.02
  2. Makoto Ueno · 8 shared papers, 2017–2024 · strength 0.79
  3. Masafumi Ikeda · 8 shared papers, 2015–2024 · strength 0.76
  4. Nobumasa Mizuno · 8 shared papers, 2015–2024 · strength 0.72
  5. Masami Miki · 3 shared papers, 2022–2026 · strength 0.70
  6. Naohiro Okano · 4 shared papers, 2022–2024 · strength 0.52
  7. Junji Furuse · 6 shared papers, 2016–2023 · strength 0.48
  8. Chigusa Morizane · 4 shared papers, 2017–2024 · strength 0.44
  9. Yasuyuki Kawamoto · 3 shared papers, 2022–2024 · strength 0.39
  10. Masato Ozaka · 3 shared papers, 2020–2024 · strength 0.37
  11. Takuji Okusaka · 5 shared papers, 2015–2023 · strength 0.37
  12. Hiroshi Ishii · 4 shared papers, 2015–2023 · strength 0.36
  13. Kentaro Sudo · 3 shared papers, 2019–2024 · strength 0.35
  14. Nobuhisa Matsuhashi · 2 shared papers, 2023–2024 · strength 0.28
  15. Kumiko Umemoto · 2 shared papers, 2023–2024 · strength 0.28
  16. Koushiro Ohtsubo · 2 shared papers, 2023–2024 · strength 0.28
  17. Shinji Itoh · 2 shared papers, 2023–2024 · strength 0.28
  18. Tomohisa Yamamoto · 2 shared papers, 2023–2025 · strength 0.28
  19. Tatsuya Ioka · 4 shared papers, 2016–2020 · strength 0.28
  20. Hiroki Yamaue · 3 shared papers, 2015–2025 · strength 0.27
  21. Nao Fujimori · 2 shared papers, 2022–2023 · strength 0.27
  22. Akinori Asagi · 2 shared papers, 2022–2024 · strength 0.26
  23. Yoshito Komatsu · 3 shared papers, 2016–2023 · strength 0.26
  24. Takahiro Tomino · 1 shared paper, 2025 · strength 0.25
  25. Tomonari Shimagaki · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.